Skip to contentA
Amphastar Pharmaceuticals, Inc.
A
AMPHAmphastar Pharmaceuticals, Inc. Q1 2023 · 10-Q
Revenue$140.02M$140.02M+16.3% vs Q1 2022 Net Income$26.03M$26.03M+7.3% vs Q1 2022 EPS Diluted$0.50$0.50+6.4% vs Q1 2022 Gross Profit$73,840,000+32.3% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Amphastar Pharmaceuticals, Inc. · CIK 1297184 · Engraved from SEC EDGAR
Operating Cash Flow$40,382,000−20.5% Free Cash Flowderived$30,905,000−30.7% Margins · derivedGross margin52.7%+6.4 pt vs Q1 2022
Operating margin23.9%+5.9 pt vs Q1 2022
Net margin18.6%−1.6 pt vs Q1 2022
ended Mar 31, 2023 · filed May 9, 2023 · 39 d after period end